Key clinical point: Surgery improved locoregional progression or recurrence rate in patients with de novo human epidermal growth factor receptor 2-positive (HER2+) metastatic inflammatory breast cancer (BC) who received first-line systemic therapy.
Major finding: Patients who underwent mastectomy had a median overall survival of 5.2 years from the date of surgery. Only one incidence of a locoregional progression or recurrence was reported 7.8 years after surgery, and pathological complete response was achieved by 10 patients, all of whom were alive at last follow-up.
Study details: Findings are from a retrospective study including 78 patients with de novo HER2+ metastatic inflammatory BC who received first-line systemic therapy, of which 41 patients underwent mastectomy with (n = 33) or without (n = 8) subsequent radiation therapy.
Disclosures: This study was funded by the Dana-Farber Cancer Institute IBC Research Fund and Reardon Family Fund. The authors declared serving as consultants or advisors or receiving speaker honorarium or travel support from, or holding stocks in several sources.
Source: Garrido-Castro AC et al. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ Breast Cancer. 2023;9:50 (Jun 2). doi: 10.1038/s41523-023-00555-w